MNKDライブシグナル | Getagraph.comで利益を最大化

売る 107828 min ago

@ $3.58

発行日: 15 2月 2024 @ 04:32

リターン: 21.26%

前回のシグナル: 2月 15 - 03:57

前回のシグナル: 買う

リターン: 1.56 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:40):

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States...

Stats
本日の出来高	399 546
平均出来高	2.89M
時価総額	1.17B
EPS	$0 ( 2024-02-27 )
次の収益日	( $0.0200 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-108.37
ATR14	$0.00700 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Prentiss Christopher B	Buy	0
2024-03-27	Sabella Lauren M	Sell	17 084	Common Stock, $.01 Par Value
2024-02-04	Tross Stuart A	Buy	15 290	Common Stock, $0.01 Par Value
2023-12-31	Tross Stuart A	Buy	1 006	Common Stock, $0.01 Par Value
2023-06-30	Tross Stuart A	Buy	4 012	Common Stock, $0.01 Par Value

INSIDER POWER
30.57
Last 95 transactions
Buy: 5 237 724 \| Sell: 2 722 728

ボリューム相関

長: -0.03 (neutral)

短: -0.24 (neutral)

Signal:(50.29) Neutral

MannKind Corp 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

MannKind Corp 相関 - 通貨/商品

0.37
( neutral )

0.15
( neutral )

0.00
( neutral )

0.51
( weak )

-0.41
( neutral )

MannKind Corp 財務諸表

Annual	2023
収益:	$198.96M
総利益:	$136.19M (68.45 %)
EPS:	$-0.0447

FY	2023
収益:	$198.96M
総利益:	$136.19M (68.45 %)
EPS:	$-0.0447

FY	2022
収益:	$99.77M
総利益:	$42.27M (42.37 %)
EPS:	$-0.440

FY	2021
収益:	$75.44M
総利益:	$36.59M (48.49 %)
EPS:	$-0.320

Financial Reports:

No articles found.

MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.